Circulating microRNAs and isomiRs as biomarkers for the initial insult and epileptogenesis in four experimental epilepsy models: The EPITARGET study.
amygdala stimulation
perforant pathway stimulation
pilocarpine
posttraumatic epilepsy
status epilepticus
traumatic brain injury
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
revised:
17
09
2024
received:
15
05
2024
accepted:
17
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
aheadofprint
Résumé
Structural epilepsies can manifest months or years after the occurrence of an initial epileptogenic insult, making them amenable for secondary prevention. However, development of preventive treatments has been challenged by a lack of biomarkers for identifying the subset of individuals with the highest risk of epilepsy after the epileptogenic insult. Four different rat models of epileptogenesis were investigated to identify differentially expressed circulating microRNA (miRNA) and isomiR profiles as biomarkers for epileptogenesis. Plasma samples were collected on day 2 and day 9 during the latency period from animals that did or did not develop epilepsy during long-term video-electroencephalographic monitoring. miRNAs and isomiRs were identified and measured in an unsupervised manner, using a genome-wide small RNA sequencing platform. Receiver operating characteristic analysis was performed to determine the performance of putative biomarkers. Two days after an epileptogenic insult, alterations in the levels of several plasma miRNAs and isomiRs predicted epileptogenesis in a model-specific manner. One miRNA, miR-3085, showed good sensitivity (but low specificity) as a prognostic biomarker for epileptogenesis in all four models (area under the curve = .729, sensitivity = 83%, specificity = 64%, p < .05). Identified plasma miRNAs and isomiRs are mostly etiology-specific rather than common prognostic biomarkers of epileptogenesis. These data imply that in preclinical and clinical studies, it may be necessary to identify specific biomarkers for different epilepsy etiologies. Importantly, circulating miRNAs like miR-3085 with high negative predictive value for epileptogenesis in different etiologies could be useful candidates for initial screening purposes of epileptogenesis risk.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Seventh Framework Programme
ID : FP7- HEALTH project 602102 [EPITARGET]
Informations de copyright
© 2024 The Author(s). Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Simonato M, Agoston DV, Brooks‐Kayal A, Dulla C, Fureman B, Henshall DC, et al. Identification of clinically relevant biomarkers of epileptogenesis—a strategic roadmap. Nat Rev Neurol. 2021;17:231–242.
Pitkanen A, Ekolle Ndode‐Ekane X, Lapinlampi N, Puhakka N. Epilepsy biomarkers—toward etiology and pathology specificity. Neurobiol Dis. 2019;123:42–58.
Enright N, Simonato M, Henshall DC. Discovery and validation of blood microRNAs as molecular biomarkers of epilepsy: ways to close current knowledge gaps. Epilepsia Open. 2018;3:427–436.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;23(116):281–297.
Dogini DB, Avansini SH, Vieira AS, Lopes‐Cendes I. MicroRNA regulation and dysregulation in epilepsy. Front Cell Neurosci. 2013;4(7):172.
Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JHM, et al. MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 2016;15:1368–1376.
Srivastava PK, Roncon P, Lukasiuk K, Gorter JA, Aronica E, Pitkanen A, et al. Meta‐analysis of microRNAs dysregulated in the hippocampel dentate gyrus of animal models of epilepsy. eNeuro. 2017;4(6):e0152‐17.2017 1‐22.
Brennan GP, Bauer S, Engel T, Jimenez‐Mateos EM, Del Gallo F, Hill TDM, et al. Genome‐wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy. Neurobiol Dis. 2020;144:105048.
Gorter JA, Iyer A, White I, Colzi A, van Vliet EA, Sisodiya S, et al. Hippocampal subregion‐specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy. Neurobiol Dis. 2014;62:508–520.
Roncon P, Soukupova M, Binaschi A, Falcicchia C, Zucchini S, Ferracin M, et al. MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine‐induced epilepsy—comparison with human epileptic samples. Sci Rep. 2015;18(5):14143.
Korotkov A, Mills JD, Gorter JA, van Vliet EA, Aronica E. Systematic review and meta‐analysis of differentially expressed miRNAs in experimental and human temporal lobe epilepsy. Sci Rep. 2017;14(7):11592.
Iori V, Iyer AM, Ravizza T, Beltrame L, Paracchini L, Marchini S, et al. Blockade of the IL‐1R1/TLR4 pathway mediates disease‐modification therapeutic effects in a model of acquired epilepsy. Neurobiol Dis. 2017;99:12–23.
Morris G, Reschke CR, Henshall DC. Targeting microRNA‐134 for seizure control and disease modification in epilepsy. EBioMedicine. 2019;45:646–654.
Vangoor VR, Reschke CR, Senthilkumar K, van de Haar LL, de Wit M, Giuliani G, et al. Antagonizing increased miR‐135a levels at the chronic stage of experimental TLE reduces spontaneous recurrent seizures. Neuroscience. 2019;39:5064–5079.
Veno MT, Reschke CR, Morris G, Connolly NMC, Su J, Yan Y, et al. A systems approach delivers a functional microRNA catalog and expanded targets for seizure suppression in temporal lobe epilepsy. Proc Natl Acad Sci USA. 2020;7(117):15977–15988.
Pitkanen A, Paananen T, Kyyriainen J, Das Gupta S, Heiskanen M, Vuokila N, et al. Biomarkers for posttraumatic epilepsy. Epilepsy Behav. 2021;121:107080.
Martinez B, Peplow PV. MicroRNAs as potential biomarkers in temporal lobe epilepsy and mesial temporal lobe epilepsy. Neural Regen Res. 2023;18:716–726.
Scheper M, Romagnolo A, Besharat ZM, Iyer AM, Moavero R, Hertzberg C, et al. miRNAs and isomiRs: serum‐based biomarkers for the development of intellectual disability and autism spectrum disorder in tuberous sclerosis complex. Biomedicine. 2022;10(8):1838.
Heiskanen M, Das Gupta S, Mills JD, van Vliet EA, Manninen E, Ciszek R, et al. Discovery and validation of circulating microRNAs as biomarkers for Epileptogenesis after experimental traumatic brain injury‐the EPITARGET cohort. Int J Mol Sci. 2023;1:24.
Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20:21–37.
Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 2008;18:610–621.
Koppers‐Lalic D, Hackenberg M, de Menezes R, Misovic B, Wachalska M, Geldof A, et al. Non‐invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget. 2016;19(7):22566–22578.
Glogovitis I, Yahubyan G, Wurdinger T, Koppers‐Lalic D, Baev V. isomiRs‐hidden soldiers in the miRNA regulatory army, and how to find them? Biomol Ther. 2020;30:11.
Pitkanen A, Henshall DC, Cross JH, Guerrini R, Jozwiak S, Kokaia M, et al. Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy. Epilepsia. 2019;60:1281–1292.
Chen M, Zhao QY, Edson J, Zhang ZH, Li X, Wei W, et al. Genome‐wide microRNA profiling in brain and blood samples in a mouse model of epileptogenesis. Epilepsy Res. 2020;166:106400.
Brindley E, Heiland M, Mooney C, Diviney M, Mamad O, Hill TDM, et al. Brain cell‐specific origin of circulating microRNA biomarkers in experimental temporal lobe epilepsy. Front Mol Neurosci. 2023;16:1230942.
Szydlowska K, Bot A, Nizinska K, Olszewski M, Lukasiuk K. Circulating microRNAs from plasma as preclinical biomarkers of epileptogenesis and epilepsy. Sci Rep. 2024;6(14):708.
van Vliet EA, Puhakka N, Mills JD, Srivastava PK, Johnson MR, Roncon P, et al. Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: focus on circulating microRNAs. Epilepsia. 2017;58:2013–2024.
Lidster K, Jefferys JG, Blumcke I, Crunelli V, Flecknell P, Frenguelli BG, et al. Opportunities for improving animal welfare in rodent models of epilepsy and seizures. J Neurosci Methods. 2016;15(260):2–25.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;22(108):5003–5008.
McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras‐Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57:833–840.
He M, Liu Y, Wang X, Zhang MQ, Hannon GJ, Huang ZJ. Cell‐type‐based analysis of microRNA profiles in the mouse brain. Neuron. 2012;12(73):35–48.
Jovicic A, Roshan R, Moisoi N, Pradervand S, Moser R, Pillai B, et al. Comprehensive expression analyses of neural cell‐type‐specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. J Neurosci. 2013;20(33):5127–5137.
Levy E. Exosomes in the diseased brain: first insights from in vivo studies. Front Neurosci. 2017;11:142.
Iwuchukwu I, Nguyen D, Beavers M, Tran V, Sulaiman W, Fannin E, et al. MicroRNA regulatory network as biomarkers of late seizure in patients with spontaneous intracerebral hemorrhage. Mol Neurobiol. 2020;57:2346–2357.
Le L, Niu L, Barter MJ, Young DA, Dalmay T, Clark IM, et al. The role of microRNA‐3085 in chondrocyte function. Sci Rep. 2020;14(10):21923.
Dasgupta N, Xu YH, Li R, Peng Y, Pandey MK, Tinch SL, et al. Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Hum Mol Genet. 2015;15(24):7031–7048.
Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood‐based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14:639–652.